The Food and Drug Administration (FDA) released a statement indicating the need for a new regulatory pathway to allow for greater oversight and to better manage risks associated with cannabidiol (CBD) products, including products currently marketed as conventional foods and dietary supplements as well as products marketed for animal use. Few details were provided about the proposed pathway. Although not discussed in the announcement, cosmetics and/or inhalable products containing CBD could be included in the new regulatory regime.
FDA is looking to Congress for help in creating a new regulatory pathway for CBD products. In the interim, CBD products (including dietary supplements, conventional foods, and animal foods) on the market are at risk of FDA enforcement as the agency deems “appropriate.”